A diverse hidradenitis suppurativa cohort: A retrospective cross-sectional study of 13,130 patients from a large US health care system database from 1995 to 2022 - 19/02/25
, Indra Adrianto, PhD a, b, d, e, f, ⁎ , Qing-Sheng Mi, MD, PhD a, d, e, f, g, h, i, j, ⁎ Abstract |
Background |
Most epidemiological studies of hidradenitis suppurativa (HS) have described homogeneous patient populations.
Objective |
To characterize demographics, modifiable health behaviors, and comorbidities of HS patients within a diverse cohort.
Methods |
A retrospective cross-sectional study of 13,130 HS patients within a health care system was conducted.
Results |
A female sex bias of ∼3:1 in all racial/ethnic subgroups was observed. Black/African American (AA) patients had a lower age at HS diagnosis than White patients (37.1 years vs 39.4 years, P < .001). A higher proportion of Black/AA females than White females with HS had body mass index in the obese range (69.9% vs 56.5%; P = .03). In contrast, fewer Black/AA males with HS had a body mass index in the obese range compared to White males (51.4% vs 61.0%; P < .001). More Black/AA patients than White patients with HS had congestive heart failure (odds ratio (OR) = 2.10, confidence interval (CI) = 1.19-3.78; P < .05), chronic pulmonary disease (OR = 1.34; CI = 1.02-1.78; P < .05), diabetes with chronic complication (OR = 1.73; CI = 1.16-2.60; P < .05), renal disease (OR = 2.66; CI = 1.67-4.34; P < .05), and Charlson comorbidity index score ≥4 (OR = 1.67; CI = 1.09-2.58; P < .05). Furthermore, male patients were more likely than female patients to have renal disease (OR = 2.62; CI = 1.66-4.14; P < .05).
Limitations |
A single-center study.
Conclusion |
Subgroups of HS patients had significant differences in demographics, risk factors, and comorbid conditions.
Le texte complet de cet article est disponible en PDF.Key words : comorbidity, demographics, epidemiology, hidradenitis suppurativa, risk factors, sex bias
Abbreviations used : AA, BMI, CCI, CI, EHR, HS, OR, SD
Plan
| Drs Young, Veenstra and Authors Loveless, Su are equally contributed to this study. |
|
| Funding sources: Research reported in this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, United States, under Award Number R01AR083553, R01AR078688, R21AR079089, and R33AR076803 to Adrianto and Mi and Henry Ford Immunology Program Research Support to Zhou, Adrianto, and Mi. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. |
|
| Patient consent: Not applicable, a minimal risk retrospective chart review in which no patient interaction will occur. |
|
| IRB approval status: Reviewed and approved by Henry Ford Health IRB; approval #12826. |
Vol 92 - N° 3
P. 487-494 - mars 2025 Retour au numéro
Article précédent
- Differentiating seborrheic keratosis from melanoma among lesions exhibiting blue-white veil: A retrospective study
- Isabella N. Dana, Nicholas R. Kurtansky, Larissa M. Pastore, James R. Xu, Zaeem H. Nazir, Stephen W. Dusza, Emmanouil Chousakos, Ofer Reiter, Cristian Navarrete-Dechent, Ralph P. Braun, Harold S. Rabinovitz, Ashfaq A. Marghoob
- FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis
- Laura K. Ferris, Jerry Bagel, Yu-Huei Huang, Andrew E. Pink, Stephen K. Tyring, Georgios Kokolakis, Amy M. DeLozier, Shu Li, Yaung-Kaung Shen, Charles Iaconangelo, Takayuki Ota, Robert Bissonnette
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?